The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Arrowhead Pharmaceuticals Inc’s stock clocked out at $69.62, down -0.77% from its previous closing price of $70.16. In other words, the price has decreased by -$0.77 from its previous closing price. On the day, 0.89 million shares were traded. ARWR stock price reached its highest trading level at $69.69 during the session, while it also had its lowest trading level at $68.0.
Ratios:
To gain a deeper understanding of ARWR’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 60.27. For the most recent quarter (mrq), Quick Ratio is recorded 4.86 and its Current Ratio is at 4.86. In the meantime, Its Debt-to-Equity ratio is 1.57 whereas as Long-Term Debt/Eq ratio is at 1.47.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 29 ’25 when Christopher Anzalone bought 51,726 shares for $69.13 per share.
Mauro Ferrari bought 7,530 shares of ARWR for $527,070 on Dec 26 ’25. On Dec 19 ’25, another insider, Waddill William D., who serves as the Director of the company, sold 8,367 shares for $67.65 each. As a result, the insider received 566,038 and left with 56,563 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 9625491456 and an Enterprise Value of 9308640256. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.40 while its Price-to-Book (P/B) ratio in mrq is 20.27. Its current Enterprise Value per Revenue stands at 11.223 whereas that against EBITDA is 76.129.
Stock Price History:
The Beta on a monthly basis for ARWR is 1.25, which has changed by 2.731915 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $72.36, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 35.68%, while the 200-Day Moving Average is calculated to be 154.30%.
Shares Statistics:
It appears that ARWR traded 2.36M shares on average per day over the past three months and 2026050 shares per day over the past ten days. A total of 135.70M shares are outstanding, with a floating share count of 125.91M. Insiders hold about 7.29% of the company’s shares, while institutions hold 81.10% stake in the company. Shares short for ARWR as of 1765756800 were 10234550 with a Short Ratio of 4.33, compared to 1763078400 on 11596104. Therefore, it implies a Short% of Shares Outstanding of 10234550 and a Short% of Float of 9.7799994.
Earnings Estimates
As of right now, 7.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$1.08, with high estimates of $0.08 and low estimates of -$1.55.
Analysts are recommending an EPS of between -$1.55 and -$5.93 for the fiscal current year, implying an average EPS of -$3.16. EPS for the following year is -$4.53, with 9.0 analysts recommending between -$2.98 and -$6.34.
Revenue Estimates
In. The current quarter, 10 analysts expect revenue to total $244.84M. It ranges from a high estimate of $425.29M to a low estimate of $9M. As of. The current estimate, Arrowhead Pharmaceuticals Inc’s year-ago sales were $2.5MFor the next quarter, 10 analysts are estimating revenue of $58.94M. There is a high estimate of $209M for the next quarter, whereas the lowest estimate is $1.8M.
A total of 14 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $599.56M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $399.8M. In the same quarter a year ago, actual revenue was $829.45MBased on 12 analysts’ estimates, the company’s revenue will be $275.94M in the next fiscal year. The high estimate is $440.1M and the low estimate is $114.2M.
